SEC Form 4 · accession 0001179110-19-002371
AbbVie Inc. · ABBV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William J Chase
Officer — EVP, Finance & Administration
Period of report
Feb 21, 2019
Accepted (ET)
Feb 22, 2019 · 5:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551152
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 par valueF1 | Feb 21, 2019 | A | 22,150 | $0.00 | A | 127,013 | D | |
| Common Stock, $0.01 par valueF2 | Feb 21, 2019 | A | 15,945 | $0.00 | A | 142,958 | D | |
| Common Stock, $0.01 par valueF3 | Feb 21, 2019 | A | 14,989 | $0.00 | A | 157,947 | D | |
| Common Stock, $0.01 par valueF4 | Feb 21, 2019 | A | 8,481 | $0.00 | A | 166,428 | D | |
| Common stock, $0.01 par valueF5 | holding | — | — | — | 501 | I | By spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F6 | $79.02 | Feb 21, 2019 | A | 60,747 | A | Feb 21, 2020 | Feb 20, 2029 | Common Stock | 60,747 | 60,747 | D |
Explanation of responses
- F1Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
- F2Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
- F3Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
- F4Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019.
- F5The reporting person disclaims beneficial ownership of these securities.
- F6Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,249 on February 21, 2020, 20,249 on February 21, 2021, and 20,249 on February 21, 2022.